NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
01 Jul 2014

European Medicines Agency renews Marketing Authorisation for ChondroCelect

Leuven (BELGIUM) – 1 July, 2014 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic Area (EEA).
30 Jun 2014

TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis

Leuven, Belgium – 30 June, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it will develop its intravenous-administered allogeneic stem cell product, Cx611, for patients suffering from early rheumatoid arthritis and for patients suffering from severe sepsis, a potentially life-threatening complication of infection.
19 Jun 2014

Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post-­Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye Disease

WALTHAM, Mass.,June 19, 2014--Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of two clinical trials with its nanotechnology-based loteprednol etabonate MPP (LE-MPP) program, KPI-121.
10 Jun 2014

CVRx® Achieves Two Significant Milestones for its Heart Failure and Hypertension Businesses

Minneapolis – June 9, 2014 – CVRx, Inc., a private medical device company, announced today it achieved two significant milestones in its heart failure and hypertension businesses.
02 Jun 2014

TiGenix completes the sale of its Dutch manufacturing facility to PharmaCell

Leuven, Belgium – 2 June, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it has completed the sale of its Dutch production facility to PharmaCell BV for a total consideration of Euro 5.75 million.
13 May 2014

TiGenix Business and Financial Update for the first quarter of 2014

Leuven, Belgium - 13 May, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, issued today a business and financial update for the first three months of 2014.
09 May 2014

St. Jude Medical Announces TOCCASTAR Clinical Trial Meets Primary Safety and Efficacy Endpoints at Heart Rhythm 2014

ST. PAUL, Minn.--(BUSINESS WIRE)-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the TOCCASTAR clinical trial at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions in San Francisco.
23 Apr 2014

Kala Pharmaceuticals Announces $22.5 Million Series B Financing

Waltham, Mass., April 23, 2014 – Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has completed a $22.5 million Series B financing.
03 Apr 2014

TiGenix licenses exclusive marketing and distribution rights for ChondroCelect to Sobi

Leuven (BELGIUM) – April 3, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it has licensed the marketing and distribution of ChondroCelect, the cell-based medicinal product for the repair of cartilage defects of the knee, to the international specialty healthcare company dedicated to rare diseases, Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI).
26 Mar 2014

AM-Pharma announces positive Phase I data on recAP, for Acute Kidney Injury

Bunnik, The Netherlands, 26 March 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.